Table 3 |
|||||
|
Prescriptions of biologicals by Rural, Remote, and Metropolitan Area (RRMA) classification system, based on DUSC data (Aug 2003–Jun 2005) |
|||||
|
RRMA |
Etanercept |
Infliximab |
Adalimumab |
Biologicals Total |
% of Total |
|
|
|||||
|
Capital cities |
18669 |
802 |
6396 |
25867 |
80.25 |
|
Other metropolitan centresa |
2124 |
52 |
826 |
3002 |
9.31 |
|
Large rural centresb |
1517 |
138 |
611 |
2266 |
7.03 |
|
Small rural centresc |
635 |
5 |
165 |
805 |
2.50 |
|
Other rural areasd |
44 |
0 |
17 |
61 |
0.2 |
|
Remote arease |
22 |
0 |
13 |
35 |
0.11 |
|
Other remote areasf |
4 |
1 |
0 |
5 |
0.02 |
|
Unknown |
164 |
1 |
28 |
193 |
0.6 |
|
|
|||||
|
a Other metropolitan centres: population > 100 000 [27] b Large rural centres: population 25 000 to 99 999 c Small rural centres: population 10 000 to 24 999 d Other rural areas: population < 10 000 e Remote areas: population > 5000 f Other remote areas: <5000 |
|||||
|
Lu et al. Australia and New Zealand Health Policy 2007 4:2 doi:10.1186/1743-8462-4-2 |
|||||